

Appln No.: 09/996,128
Amendment Dated: August 7, 2005
Reply to Office Action of May 6, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A method for treating melanoma in a mammalian subject, comprising the step of administering to the subject an immunologically-effective amount of a xenogeneic differentiation antigen of the same type as a differentiation antigen expressed by melanoma cells of the subject.
2. (original) The method according to claim 1, wherein the xenogeneic melanoma-associated differentiation antigen is tyrosinase.
3. (withdrawn) The method according to claim 1, wherein the xenogeneic melanoma-associated differentiation antigen is gp75.
- 4 (original) The method according to claim 1, wherein the xenogeneic antigen is a human differentiation antigen, and the subject is a non-human mammal.
5. (original) The method according to claim 4, wherein the xenogeneic melanoma-associated differentiation antigen is tyrosinase.
6. (withdrawn) The method according to claim 4, wherein the xenogeneic melanoma-associated differentiation antigen is gp75.
7. (withdrawn) The method according to claim 1, wherein the xenogeneic differentiation antigen is a murine differentiation antigen.
8. (withdrawn) The method according to claim 7, wherein the subject is a human.
9. (withdrawn) The method according to claim 7, wherein the subject is a dog.
10. (original) The method according to claim 1, wherein the xenogeneic melanoma-associated differentiation antigen is administered as a vector comprising a DNA sequence encoding the xenogeneic therapeutic melanoma-associated differentiation antigen under the control of a promoter which promotes expression of the xenogeneic melanoma-associated differentiation antigen in the subject.

Appln No.: 09/996,128
Amendment Dated: August 7, 2005
Reply to Office Action of May 6, 2005

11. (original) The method according to claim 10, wherein the xenogeneic melanoma-associated differentiation antigen is a human differentiation antigen.

12. (original) The method according to claim 11, wherein the xenogeneic melanoma-associated differentiation antigen is human tyrosinase.

13. (withdrawn) The method according to claim 11, wherein the xenogeneic melanoma-associated differentiation antigen is human gp75.

14. (withdrawn) The method according to claim 10, wherein the xenogeneic melanoma-associated differentiation antigen is a murine differentiation antigen.

15. (withdrawn) The method according to claim 14, wherein the xenogeneic melanoma-associated differentiation antigen is murine tyrosinase.

16. (withdrawn) The method according to claim 14, wherein the xenogeneic melanoma-associated differentiation antigen is murine gp75.

17. (original) The method according to claim 10, wherein the plasmid has the sequence given by sequence ID No. 1 and the subject is a non-human.

18. (withdrawn) The method according to claim 10, wherein the plasmid has the sequence given by sequence ID No. 2 and the subject is not a mouse.

19. (original) The method according to claim 1, further comprising the step of administering a syngeneic differentiation antigen of the same type as the xenogeneic differentiation antigen, said syngeneic differentiation antigen being administered at the same time as or subsequent to the xenogeneic differentiation antigen.

20. (original) A method for treating canine malignant melanoma in a dog suffering from canine malignant melanoma comprising administering to the dog an immunologically-effective amount of a xenogeneic differentiation antigen of the same type as a differentiation antigen expressed by melanoma cells of the dog.

21. (original) The method according to claim 20, wherein the xenogeneic melanoma-associated differentiation antigen is tyrosinase.

22. (original) The method according to claim 20, wherein the xenogeneic melanoma-associated differentiation antigen is human tyrosinase.

Appln No.: 09/996,128
Amendment Dated: August 7, 2005
Reply to Office Action of May 6, 2005

23. (original) The method according to claim 20, wherein the xenogeneic melanoma-associated differentiation antigen is administered as a vector comprising a DNA sequence encoding the xenogeneic therapeutic melanoma-associated differentiation antigen under the control of a promoter which promotes expression of the xenogeneic melanoma-associated differentiation antigen in the dog.

24. (original) The method according to claim 23, wherein the vector has the sequence given by Seq. ID. NO. 1.

25. (withdrawn) The method according to claim 23, wherein the vector has the sequence given by Seq. ID. NO. 2.

26. (withdrawn) A vector comprising the sequence given by Seq. ID No. 1.

27. (withdrawn) A vector comprising the sequence given by Seq. ID No. 2.

28. (new) The method of claim 1, wherein the differentiation antigen is selected from the group consisting of Melan-A/Mart-1, Pmel17, tyrosinase and gp75.

29. (new) The method of claim 20, wherein the differentiation antigen is selected from the group consisting of Melan-A/Mart-1, Pmel17, tyrosinase and gp75.